MA53977B1 - Compositions stables du sémaglutide et leurs utilisations - Google Patents

Compositions stables du sémaglutide et leurs utilisations

Info

Publication number
MA53977B1
MA53977B1 MA53977A MA53977A MA53977B1 MA 53977 B1 MA53977 B1 MA 53977B1 MA 53977 A MA53977 A MA 53977A MA 53977 A MA53977 A MA 53977A MA 53977 B1 MA53977 B1 MA 53977B1
Authority
MA
Morocco
Prior art keywords
semaglutide
stable compositions
compositions
glp
histidine
Prior art date
Application number
MA53977A
Other languages
English (en)
Other versions
MA53977A (fr
Inventor
Joakim Lundqvist
Dorthe Engelund
Søren Jensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/EP2019/079214 external-priority patent/WO2020084126A1/fr
Publication of MA53977A publication Critical patent/MA53977A/fr
Publication of MA53977B1 publication Critical patent/MA53977B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques de sémaglutide de peptide glp-1 comprenant un stabilisant tel que l'histidine, leur préparation, des kits comprenant de telles compositions ainsi que leurs utilisations médicales.
MA53977A 2018-10-26 2019-10-25 Compositions stables du sémaglutide et leurs utilisations MA53977B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18202801 2018-10-26
PCT/EP2019/079214 WO2020084126A1 (fr) 2018-10-26 2019-10-25 Compositions de sémaglutide stables et leurs utilisations

Publications (2)

Publication Number Publication Date
MA53977A MA53977A (fr) 2022-02-09
MA53977B1 true MA53977B1 (fr) 2023-11-30

Family

ID=64051384

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53977A MA53977B1 (fr) 2018-10-26 2019-10-25 Compositions stables du sémaglutide et leurs utilisations

Country Status (1)

Country Link
MA (1) MA53977B1 (fr)

Also Published As

Publication number Publication date
MA53977A (fr) 2022-02-09

Similar Documents

Publication Publication Date Title
MA46990B1 (fr) Compositions glp-1 et ses utilisations
MA57972B1 (fr) Inhibiteurs de parp1
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA51530B1 (fr) Composés cycliques fondus
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA50406B1 (fr) Inhibiteurs pyrazole de magl
WO2019018451A3 (fr) Compositions et méthodes de prévention et de traitement d'effets de proximité induits par rayonnement provoqués par un rayonnement ou une radiothérapie
NZ786543A (en) Compounds active towards nuclear receptors
MA62992B1 (fr) Formulations de capsules
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations
FR3074421B1 (fr) Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite